{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:21:17Z","timestamp":1787170877224,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.autrev.2024.103736","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T02:44:09Z","timestamp":1735526649000},"page":"103736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review"],"prefix":"10.1016","volume":"24","author":[{"given":"Dimitris","family":"Challoumas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Moots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwidimi","family":"Ndosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe Rutter","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.autrev.2024.103736_bb0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.autrev.2024.103736_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103736_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0030","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"7","key":"10.1016\/j.autrev.2024.103736_bb0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103736_bb0040","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and","volume":"18","author":"Haddaway","year":"2022","journal-title":"Open Synthesis Campbell Systematic Reviews"},{"issue":"13","key":"10.1016\/j.autrev.2024.103736_bb0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"issue":"10143","key":"10.1016\/j.autrev.2024.103736_bb0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0055","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind","volume":"75","author":"Morand","year":"2023","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"issue":"10381","key":"10.1016\/j.autrev.2024.103736_bb0065","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"10381","key":"10.1016\/j.autrev.2024.103736_bb0070","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2024.103736_bb0075","article-title":"Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial [abstract]","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.autrev.2024.103736_bb0080","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0085","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"issue":"17","key":"10.1016\/j.autrev.2024.103736_bb0090","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0095","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0100","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s10067-023-06660-2","article-title":"Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease","volume":"42","author":"Junfei","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103736_bb0105","article-title":"JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"9","author":"Hou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2024.103736_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/annrheumdis-2022-eular.4186","article-title":"POS0014\u00a0efficacy and safety of JAK inhibitors in refractory or initial treatment of adult onset still\u2019s disease","volume":"81","author":"Chen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103736_bb0115","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/annrheumdis-2021-eular.2210","article-title":"AB0772\u00a0JAK inhibitors in refractory adult and childhood onset still\u2019s disease","volume":"80","author":"Gillard","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103736_bb0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0130","doi-asserted-by":"crossref","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0140","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0145","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0150","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus","volume":"178","author":"Presto","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaad.2022.02.027","article-title":"Treatment of lichen planopilaris with baricitinib: a retrospective study","volume":"87","author":"Moussa","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0165","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaad.2020.05.104","article-title":"Tofacitinib in the treatment of lichen planopilaris: a retrospective review","volume":"83","author":"Plante","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12656","article-title":"Tofacitinib for the treatment of lichen planopilaris: a case series","volume":"31","author":"Yang","year":"2018","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/bjd\/ljad129","article-title":"Abrocitinib as a novel treatment for lichen sclerosus","volume":"189","author":"Bao","year":"2023","journal-title":"Br J Dermatol"},{"issue":"40","key":"10.1016\/j.autrev.2024.103736_bb0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2023.08.001","article-title":"Treatment of erosive vulvovaginal lichen planus with tofacitinib: a case series","author":"Kassels","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.autrev.2024.103736_bb0185","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jid.2022.01.015","article-title":"Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective","volume":"142","author":"Brumfiel","year":"2022","journal-title":"Open-Label Study J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103736_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15848","article-title":"Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series","volume":"35","author":"Sun","year":"2022","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.autrev.2024.103736_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with Morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"Supplement 1","key":"10.1016\/j.autrev.2024.103736_bb0200","first-page":"106","article-title":"Study of Tofacitinib for the treatment of chronic Pouchitis: baseline immune activity determines induction response in a small preliminary cohort","volume":"37","author":"Davies","year":"2022","journal-title":"Journal of Gastroenterology and Hepatology [Internet]"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0205","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ecco-jcc\/jjad194","article-title":"Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER multicentre case series","volume":"18","author":"Ribaldone","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103736_bb0210","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ibd\/izac147","article-title":"Tofacitinib for the treatment of pouch-related disorders: a case series","volume":"28","author":"Dalal","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.autrev.2024.103736_bb0215","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ibd\/izad011","article-title":"Treatment of chronic inflammatory pouch conditions with Tofacitinib: a case series from 2 tertiary IBD centers in the United States","volume":"29","author":"Akiyama","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103736_bb0225","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103736_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109241","article-title":"Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: a pilot study","volume":"247","author":"Liu","year":"2023","journal-title":"Clin Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2024.103736_bb0235","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103736_bb0240","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103736_bb0250","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103736_bb0255","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0265","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103736_bb0270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis","volume":"80","author":"Ding","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0275","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"issue":"12","key":"10.1016\/j.autrev.2024.103736_bb0280","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0285","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaad.2022.08.025","article-title":"Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study","volume":"87","author":"Zhao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0290","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of Tofacitinib in refractory dermatomyositis: An open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0295","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.41944","article-title":"Long-term extension study of tofacitinib in refractory dermatomyositis","volume":"74","author":"Paik","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"Supplement 9","key":"10.1016\/j.autrev.2024.103736_bb0300","first-page":"3731","article-title":"Determining the long-term safety and efficacy of JAK inhibitors in the treatment of dermatomyositis: a retrospective cohort study","volume":"74","author":"Rangaswamy","year":"2022","journal-title":"Arthritis and Rheumatology"},{"key":"10.1016\/j.autrev.2024.103736_bb0305","first-page":"kead404","article-title":"Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients","volume":"16","author":"Beckett","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103736_bb0310","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: a pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0315","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103736_bb0320","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2023-eular.6187","article-title":"AB0849\u00a0JAK inhibitors improve seropositive refractory myositis: single center experience","volume":"82","author":"Kosmetatou","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.autrev.2024.103736_bb0330","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"Zhang","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.autrev.2024.103736_bb0335","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/IJGM.S414267","article-title":"Efficacy of JAK inhibitors versus DMARDs in the treatment of polymyalgia rheumatica in China","author":"Gu","year":"2023","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.autrev.2024.103736_bb0340","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/annrheumdis-2021-eular.3435","article-title":"AB0379\u00a0BARICITINIB in polymyalgia rheumatica and giant cell arteritis: report of six cases","volume":"80","author":"Camellino","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103736_bb0345","first-page":"1559","article-title":"AB0709\u00e2\u20ac\u2026effectiveness of JANUS kinase inhibitors in giant cell arteritis in clinical practice. Real-world clinical practice study and literature review","volume":"82","author":"\u00c3lvarez-Reguera","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.autrev.2024.103736_bb0350","doi-asserted-by":"crossref","first-page":"1187584","DOI":"10.3389\/fimmu.2023.1187584","article-title":"Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden","volume":"14","author":"Eriksson","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0355","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0360","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.31138\/mjr.230929.su","article-title":"Successful use of tofacitinib in refractory takayasu arteritis: a case series","volume":"34","author":"Mv","year":"2023","journal-title":"Mediterr J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103736_bb0370","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu\u2019s arteritis","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2024.103736_bb0375","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.autrev.2024.103736_bb0390","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0395","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamadermatol.2020.3095","article-title":"Tofacitinib for the treatment of nail lesions and palmoplantar Pustulosis in synovitis, acne, Pustulosis, hyperostosis, and osteitis syndrome","volume":"157","author":"Li","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0405","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-023-00817-8","article-title":"Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, and AGS)","volume":"21","author":"Kanazawa","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0410","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103736_bb0415","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103736_bb0420","doi-asserted-by":"crossref","first-page":"820586","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of Tofacitinib in 24 cases of pediatric rheumatic diseases: single Centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.autrev.2024.103736_bb0425","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2021.12.016","article-title":"Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib","volume":"98","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0435","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0440","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2024.103736_bb0445","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103736_bb0450","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.autrev.2024.103736_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(24)00033-X","article-title":"JAK inhibitors-friend or foe?","volume":"6","author":"The Lancet Rheumatology","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103736_bb0460","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103736_bb0465","series-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","author":"FDA","year":"2021"},{"key":"10.1016\/j.autrev.2024.103736_bb0470","series-title":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","author":"EMA","year":"2022"},{"key":"10.1016\/j.autrev.2024.103736_bb0475","series-title":"Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality","author":"MHRA","year":"2023"},{"issue":"1","key":"10.1016\/j.autrev.2024.103736_bb0495","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.autrev.2024.103736_bb0500","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103736_bb0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103736_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"35","key":"10.1016\/j.autrev.2024.103736_bb0515","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T05:28:39Z","timestamp":1740288519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1568997224002271"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103736","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103736"}}